Your search for pancreatic cancer matches 229 pages

Showing 101 - 150


Pancreatic Cancer

Has a New Standard of Care for Metastatic Pancreatic Cancer Been Established?

For a number of years following the approval of gemcitabine for advanced pancreatic cancer, one phase III clinical trial after the next failed to demonstrate a survival benefit of combination chemotherapy compared to gemcitabine alone. Even the one positive study from the mid-2000s—the PA.3 trial...

pancreatic cancer

Addition of Nab-Paclitaxel to Gemcitabine Improves Survival in Previously Untreated Metastatic Pancreas Cancer 

In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of albumin-bound paclitaxel (nab-paclitaxel [Abraxane]) to gemcitabine in patients with previously untreated...

Pancreatic Cancer

Long-Term CONKO-001 Results: Adjuvant Therapy Improves Survival 

From 12% to 15% of the approximately 45,000 patients diagnosed with pancreas adenocarcinoma undergo a potentially curative resection each year in North America, translating into roughly 5,000 to 7,000 patients who are candidates for adjuvant therapy. About 80% of these patients will relapse and...

pancreatic cancer

Adjuvant Gemcitabine Improves Long-Term Survival in Patients With Resected Pancreatic Cancer

An initial report from the phase III Charité Onkologie (CONKO) 001 trial of adjuvant gemcitabine vs observation in patients with completely resected pancreas cancer showed that gemcitabine treatment was associated with a significant prolongation of disease-free survival.1 As reported in JAMA by...

Pancreatic Cancer

January Is National Pancreatic Cancer Clinical Trials Awareness Month

January marks the annual observance of National Pancreatic Cancer Clinical Trials Awareness Month.  The 5-year survival rate of pancreatic cancer is just 6%. In the effort to highlight the urgent need to improve the survival rate for this disease, the Pancreatic Cancer Action Network is educating...

Pancreatic Cancer

High Expression of hENT1 Can Predict Better Survival Among Patients on Postsurgical Gemcitabine

High levels of expression of the human equilibrative nucleoside transporter 1 (hENT1) were associated with longer median survival of patients with pancreatic adenocarcinoma receiving gemcitabine, according to an analysis of clinical data and cancer tissue collected from the European Study Group for ...

Pancreatic Cancer

CYB5A Induces Autophagy, and Higher Expression Improves Survival in Pancreatic Cancer

Loss of 18q22.3 is a prognostic marker in pancreatic ductal adenocarcinoma. In a study reported in the Journal of the National Cancer Institute, Giovannetti and colleagues assessed the role of 18q22.3-encoded CYB5A in pancreatic cancer prognosis and autophagy modulation. In the study, both resected ...

pancreatic cancer

University of Pittsburgh Researchers Awarded More than $1 Million by NIH to Study New Treatments for Pancreatic Cancer Patients

The National Institutes of Health (NIH) has awarded a 5-year grant of more than $1.5 million to Herbert J. Zeh III, MD, and Michael T. Lotze, MD, at the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, to study a novel treatment for pancreatic ductal ...

pancreatic cancer

Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer

Overall survival was improved in metastatic pancreatic cancer patients through an innovative immunotherapy strategy in a multicenter study reported at the 2014 Gastrointestinal Cancers Symposium.1 “This is the first time a randomized study has shown that immunotherapy is effective in pancreatic...

colorectal cancer
pancreatic cancer

GI Symposium Presentations Include Important Updates in Treatment and Prognosis of Pancreatic and Colorectal Cancers

More than 650 studies were presented at the 2014 Gastrointestinal Cancers Symposium, which attracted a multidisciplinary group of more than 3,500 medical, surgical, and radiation oncologists and gastroenterologists. The following briefs highlight a handful of noteworthy studies from the meeting....

pancreatic cancer

Learning to Live in the Moment

I’ve been health conscious all my life. I have never smoked, I eat a healthy diet, and I have maintained a near-daily exercise routine since I was 20. I’m also steadfast about keeping yearly medical checkups and screenings. So when I felt a sharp, lightning-bolt of pain that went from the top of my ...

Breast Cancer
Colorectal Cancer
Lung Cancer
Pancreatic Cancer

ASCO Committee Defines Clinically Meaningful Goals for Clinical Trials in Pancreas, Breast, Lung, and Colorectal Cancers

The ASCO Cancer Research Committee recently convened four disease-specific working groups—in pancreas, breast, lung, and colon cancers—to “consider the design of future clinical trials that would produce results that are clinically meaningful to patients.” An ASCO perspective statement, reported in ...

pancreatic cancer

Ongoing Clinical Trials Actively Recruiting Patients  With Pancreatic Cancer

The information in this Clinical Trials Resource Guide includes details of actively recruiting clinical studies of patients with pancreatic cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. The studies presented here are nonrandomized,...

Pancreatic Cancer

Research Insights From the AACR Special Conference on Pancreatic Cancer

Pancreatic cancer still kills 40,000 Americans a year out of approximately 44,000 diagnosed. While advances in diagnosis and treatment are extending the lives of patients with other cancers, pancreatic ductal adenocarcinoma remains the second most lethal tumor (behind lung cancer). While a magic...

pancreatic cancer

Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy

The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.1 “Patients...

Pancreatic Cancer

Study Finds New Genetic Risk Markers in Pancreatic Cancer

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the disease, report scientists from ­Dana-Farber Cancer Institute and other institutions worldwide. The markers are variations in the inherited DNA...

pancreatic cancer

FDA Grants Fast Tract Designation to Investigational Combination Therapy In Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme Therapeutics’ program investigating pegylated recombinant human hyaluronidase (PEGPH20) in combination with gemcitabine and albumin-bound paclitaxel (nab-paclitaxel [Abraxane]) for the treatment of patients...

pancreatic cancer

Early Study Reports Modified Vitamin D Has Potential in Treatment for Pancreatic Cancer

Researchers at the Salk Institute have reported on a synthetic derivative of vitamin D able to collapse the barrier of cells shielding pancreatic tumors, making this challenging cancer more susceptible to therapeutic drugs. The discovery has led to human trials for pancreatic cancer, even in...

Pancreatic Cancer

Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio

Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the way for future studies of novel poly(ADP-ribose) polymerases (PARP) inhibitors in this challenging...

pancreatic cancer

Vitamin D Deficiency Is Prevalent Among Patients With Advanced Pancreatic Cancer

Vitamin D deficiency was highly prevalent among patients newly diagnosed with advanced pancreatic cancer, and black patients had statistically significantly lower levels than white patients, according to a recent study reported by Katherine Van Loon, MD, MPH, of the UCSF Helen Diller Family...

colorectal cancer
pancreatic cancer

Peripheral Nerve Schwann Cells Migrate to Pancreas and Colon Cancer Cells Before Invasion

In a study reported in the Journal of the National Cancer Institute,  Demir and colleagues used novel three-dimensional migration and Schwann cell outgrowth assays to monitor the timing and specificity of Schwann cell migration and cancer invasion toward peripheral neurons through digital...

pancreatic cancer

Pancreatic Cancer in 2014

Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in men and women in the United States. This year, about 46,000 people in this country will be diagnosed with pancreatic cancer, and more than 39,000 will die of the disease. The ASCO Post recently spoke with Margaret A....

pancreatic cancer

Study Sheds Light on Factors That May Contribute to Pancreatic Cancer

New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings were recently published early online in Cancer.1 Pancreatic cancer is usually detected at a very late stage and has a 5-year survival rate of less than 5%....

pancreatic cancer

Mitochondrial Respiration as Target in KRAS-Mutant Pancreatic Cancer

Targeting of oncogenes can produce tumor shrinkage, but the frequency of relapse indicates that a population of tumor cells survives oncogene inhibition. In a study in a KRAS-mutant pancreatic ductal adenocarcinoma mouse model reported in Nature, Viale and colleagues found that a subpopulation of...

pancreatic cancer

WEE1 Inhibition Sensitizes Pancreatic Cancer to PARP Inhibitor Radiosensitization

In a study reported in Clinical Cancer Research, Karnak and colleagues found that WEE1 kinase inhibition increased the sensitivity of pancreas cancer to the radiosensitizing effects of poly(ADP-ribose) polymerase (PARP) inhibition. Treatment of human pancreatic cancer AsPC-1 and MiaPaCa-2 cells...

pancreatic cancer

Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...

pancreatic cancer

Choice for Metastatic Pancreatic Cancer: FOLFIRINOX or Gemcitabine/Nab-Paclitaxel?

The choice between FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) vs the combination of gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) for first-line treatment of metastatic pancreatic cancer is not much of a contest, judging by a discussion of...

Pancreatic Cancer

Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly

A less intensive regimen of nab-paclitaxel (Abraxane) plus gemcitabine appears to be as efficacious as the standard regimen in first-line treatment for metastatic pancreatic cancer, but less toxic and far less expensive, according to a study that earned a Merit Award at the 2015 Gastrointestinal...

pancreatic cancer

Pancreatic Cancer: Latest Drug Development Hits and Misses

Targeting one of the deadliest cancers and seeking to fill an unmet need, drug development in pancreatic cancer is an area of high interest. This was certainly the case at the 2015 Gastrointestinal Cancers Symposium, where results were impressive for some novel agents but disappointing for several...

pancreatic cancer

FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable

Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a negative surgical margin rate exceeding 96%. The study earned a Merit Award at the 2015...

gynecologic cancers
pancreatic cancer

Human Reovirus Formulation Gets Orphan Drug Designation in Ovarian and Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of ovarian and pancreatic cancer. The reovirus’s primary mode of activity is to infect and selectively target tumors...

Colorectal Cancer
Pancreatic Cancer
Gastrointestinal Cancer

New Data Reported in Colorectal, Gastric, and Pancreatic Cancers

The 2015 Gastrointestinal Cancers Symposium, held January 15–17 in San Francisco, attracted almost 4,000 attendees, who heard or viewed data from nearly 800 scientific abstracts and lectures. Here are our summaries of some of the many important developments from the meeting. Bevacizumab Plus...

Pancreatic Cancer

Heal Thy Patient … Reflections on the Human Side of Medicine

The first time I met Mrs. X and her husband was to discuss the surgical treatment options for pancreatic cancer. She had just been diagnosed with pancreatic cancer at her local hospital and was being referred to a tertiary care center for operative management. Mrs. X and her husband were no...

Lung Cancer
Pancreatic Cancer
Geriatric Oncology

Chemotherapy Trial Results Overestimate Survival for Elderly Medicare Patients With Lung and Pancreatic Cancers

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Elizabeth B. Lamont, MD, MS, of...

pancreatic cancer

FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...

pancreatic cancer
issues in oncology

Many Miles to Go: Targeted Treatment Based on Whole-Genome Sequencing

The ability to do genomic analysis of patients’ tumors holds great promise for revolutionizing cancer treatment, and genomics has already made some great strides. However, the Individualized Molecular Pancreatic Cancer Therapy ­(IMPaCT) trial is a cautionary tale about the hurdles involved in...

Skin Cancer
Breast Cancer
Multiple Myeloma
Leukemia
Colorectal Cancer
Prostate Cancer
Pancreatic Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates

For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....

Pancreatic Cancer

Novel Enzyme Improves Outcomes in Subset of Patients With Pancreatic Cancer

Patients with stage IV pancreatic cancer who received a novel enzyme along with standard chemotherapy experienced a doubling in progression-free survival, compared to those given chemotherapy alone, in a study presented at the 2015 ASCO Annual Meeting.1 Response rates and median duration of...

Pancreatic Cancer

FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration has approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. The effectiveness of...

Pancreatic Cancer

Irinotecan Liposome Injection Plus Fluorouracil/Leucovorin to Treat Patients With Metastatic Pancreatic Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On October 22, 2015, irinotecan liposome injection (Onivyde)...

Pancreatic Cancer

Clinical Trials Actively Recruiting Patients With Pancreatic Cancer

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with pancreatic cancer. The trials are investigating preoperative rehabilitation; chimeric antigen receptors; T-cell transplants; combination chemotherapy; chemoradiotherapy; ...

pancreatic cancer

Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer

In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...

issues in oncology
pancreatic cancer

Phase II Study Shows No Benefit of Adding Vismodegib to Gemcitabine in Metastatic Pancreatic Cancer

In a phase II study reported in the Journal of Clinical Oncology, Catenacci et al found no benefit of adding vismodegib (Erivedge) to gemcitabine in patients with metastatic pancreatic cancer. Sonic hedgehog (SHH), an activating ligand of the smoothened receptor (SMO) inhibited by vismodegib, has...

pancreatic cancer
issues in oncology
issues in oncology
issues in oncology

Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones

In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...

pancreatic cancer

Preclinical Study Reveals Why Chemotherapy May Be Compromised in Patients With Pancreatic Cancer

A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer and perhaps point to new approaches to treatment, including enhancing gemcitabine's ability to stop tumor growth. The MD...

pancreatic cancer
issues in oncology

Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis

Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...

pancreatic cancer

Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Preclinical Models

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy—even when used without chemotherapy or radiation—can boost survival from pancreatic cancer by more than 75%. The findings are promising, and human clinical...

pancreatic cancer

FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...

pancreatic cancer

Ruxolitinib-Capecitabine May Benefit Patients With Gemcitabine-Pretreated Metastatic Pancreatic Cancer With Systemic Inflammation

In a randomized phase II trial reported in the Journal of Clinical Oncology, Hurwitz et al found no significant survival benefit of adding the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) to capecitabine in patients with advanced pancreatic adenocarcinoma who had treatment failure with gemcitabine....

pancreatic cancer

Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...

Advertisement

Advertisement



Advertisement